Sanofi, Escherichia coli and J&J

Sanofi Ends Trial for E. Coli Shot and Takes a $250 Million Hit
Sanofi and Johnson & Johnson ended development of an experimental vaccine after it failed to adequately protect against an invasive form of the digestive pathogen E. coli.
J&J, Sanofi stop E.coli vaccine trial due to low effectiveness
Johnson & Johnson and partner Sanofi will stop a late-stage trial of an experimental vaccine to prevent infections caused by the E.coli bacteria due to a lack of sufficient efficacy, the companies said on Thursday.
J&J stops Phase III trial of Sanofi’s E. Coli vaccine citing ‘disappointing’ results
The company said it will stop the Phase III trial of ExPEC after interim results found it failed to demonstrate efficacy over placebo.
Johnson & Johnson halts late-stage E.coli vaccine trial after poor results
Pharmaceutical giants Johnson & Johnson and Sanofi have stopped a late-stage clinical trial for their experimental E.coli vaccine after results failed to demonstrate sufficient efficacy. The companies announced on Thursday that while the vaccine showed no safety concerns,
J&J to discontinue E.coli vaccine candidate study
Johnson & Johnson said on Thursday it will discontinue a late-stage study of an experimental E.coli vaccine it was developing in partnership with Sanofi. The drugmaker said its decision was based on t
Sanofi and J&J discontinue late stage trial of their experimental E.coli vaccine
Sanofi (NASDAQ:SNY) said on Thursday that it is discontinuing the late-stage trial for its vaccine to prevent E. coli bacteria infection as it failed to demonstrate sufficient efficacy. The vaccine for extraintestinal pathogenic E.
Nature7mon
Purification of plasmid DNA using selective precipitation by compaction agents
Overnight cultures of E. coli (2 ml) were subjected to alkaline lysis, as in the large-scale separation. Cell debris was removed by centrifugation and plasmid was precipitated by 0.7 volume of ...
Fairfax Times28d
Centreville High students’ research reports finding DNA residue in Pfizer COVID vaccines
One experiment showed that the plasmid DNA can transform into Escherichia coli, or E. coli, cells, which are bacteria commonly found in human and animal intestines, according to the CDC.
Hosted on MSN4mon
Pathogenic system found on Providencia rustigianii has virulence gene akin to Salmonella's
Salmonella and E. coli are well-known bacteria that cause ... rustigianii carries a cytolethal distending toxin virulence gene on its plasmid. Elimination of this gene did not reduce the ...
Nature15y
Control and benefits of CP4-57 prophage excision in Escherichia coli biofilms
The chromosomal hha gene (high hemolysin activity) of E. coli was first identified in a search for mutants that overproduced the toxin, α-hemolysin, from a plasmid-encoded hemolytic hly operon ...
Food Safety News6d
Publisher’s Platform: Combating E. coli — A call for vigilance in food safety practices
Escherichia coli, commonly known as E. coli, is a versatile bacterium. While many strains are harmless and a natural part of our intestinal ...
The Scientist1y
Choosing the Best Reporter Assay
Reporter genes are generally joined to a regulatory DNA sequence in an expression vector that is usually propagated in Escherichia coli before transfection into ... with the experimental reporter ...